Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Suspended 1Recruiting 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 1Locally Advanced Rectal Adenocarcinoma 1Colorectal Neoplasms 1

Interventions

Specimen Handling 655pembrolizumab 608Magnetic Resonance Spectroscopy 561Carboplatin 449Cisplatin 398Cyclophosphamide 396Biopsy 380Nivolumab 325Paclitaxel 323Gemcitabine 317Radiotherapy 298Bevacizumab 248Dexamethasone 223fludarabine 215Docetaxel 202durvalumab 195Oxaliplatin 189venetoclax 186atezolizumab 183Fluorouracil 177Rituximab 176Pemetrexed 173Capecitabine 170Radiation 168Doxorubicin 166Radiosurgery 161Ipilimumab 147Etoposide 142Leucovorin 140Lenalidomide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
sotigalimab × 90 days × Clear all
NCT05419479 2026-06-04

Switch Maintenance in Pancreatic

Dana-Farber Cancer Institute

Phase 1/2 Suspended
46 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT04130854 2026-05-06

INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer

University of Texas Southwestern Medical Center

Phase 2 Completed
58 enrolled
Gastrointestinal

Locally Advanced Rectal Adenocarcinoma

NCT02600949 2026-04-24

Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1 Recruiting
300 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡